NASDAQ:MDWD
MediWound Ltd. Stock News
$18.24
+0.580 (+3.28%)
At Close: Apr 26, 2024
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
02:57pm, Sunday, 14'th Nov 2021 Benzinga
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Among the
MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care
07:30am, Monday, 04'th Oct 2021
EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar
MediWound to Present at Upcoming Investor Conferences
04:14pm, Friday, 03'rd Sep 2021
YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions fo
Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript
05:09pm, Tuesday, 10'th Aug 2021
Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript
MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates
10:07am, Tuesday, 10'th Aug 2021
MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 6.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MediWound Reports Second Quarter Financial Results
07:00am, Tuesday, 10'th Aug 2021
Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year
MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021
04:05pm, Monday, 02'nd Aug 2021
YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and
MediWound: Disappointing Thus Far But Still A Strong Buy
06:00am, Friday, 30'th Jul 2021
MediWound: Disappointing Thus Far But Still A Strong Buy
MediWound: Adjusting My Strategy After NexoBrid CRL
02:11pm, Wednesday, 28'th Jul 2021
MediWound: Adjusting My Strategy After NexoBrid CRL
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
09:36am, Monday, 26'th Jul 2021
MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma s
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
07:00am, Monday, 26'th Jul 2021
Data Expected End of 2021
MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients
08:18am, Tuesday, 20'th Jul 2021
MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns. The 145-subject study met its three primary endpoints.
MDWD Stock Increases Over 15% Pre-Market: Why It Happened
08:13am, Tuesday, 20'th Jul 2021
The stock price of Mediwound Ltd (NASDAQ: MDWD) increased by over 15% pre-market. This is why it happened.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD
10:45am, Sunday, 18'th Jul 2021
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).
Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers
